• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Vickers Philip J.

    4/3/26 4:05:32 PM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AKBA alert in real time by email
    SEC FORM 3SEC Form 3
    FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number:3235-0104
    Estimated average burden
    hours per response:0.5
    1. Name and Address of Reporting Person*
    Vickers Philip J.

    (Last)(First)(Middle)
    C/O AKEBIA THERAPEUTICS, INC
    245 FIRST STREET

    (Street)
    CAMBRIDGE MASSACHUSETTS 02142

    (City)(State)(Zip)

    UNITED STATES

    (Country)
    2. Date of Event Requiring Statement (Month/Day/Year)
    04/01/2026
    3. Issuer Name and Ticker or Trading Symbol
    Akebia Therapeutics, Inc. [ AKBA ]
    3a. Foreign Trading Symbol
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    XDirector10% Owner
    Officer (give title below)Other (specify below)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    XForm filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date ExercisableExpiration DateTitleAmount or Number of Shares
    Explanation of Responses:
    Remarks:
    No securities are beneficially owned.
    /s/ Carolyn M. Rucci, attorney-in-fact for Philip J. Vickers04/03/2026
    ** Signature of Reporting PersonDate
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    * Form 3: SEC 1473 (03-26)
    Get the next $AKBA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AKBA

    DatePrice TargetRatingAnalyst
    6/4/2025$8.00Buy
    H.C. Wainwright
    4/28/2025$7.00Outperform
    Leerink Partners
    4/1/2025$6.00Buy
    Jefferies
    11/29/2023$4.00Buy
    BTIG Research
    8/28/2023$3.75Neutral → Buy
    H.C. Wainwright
    5/31/2023$2.00 → $4.00Neutral → Overweight
    Piper Sandler
    3/31/2022$10.00 → $2.00Buy → Neutral
    H.C. Wainwright
    3/31/2022Buy → Hold
    Needham
    More analyst ratings

    $AKBA
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Akebia Therapeutics Inc.

    SCHEDULE 13G - Akebia Therapeutics, Inc. (0001517022) (Subject)

    5/12/26 9:45:20 AM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Akebia Therapeutics Inc.

    10-Q - Akebia Therapeutics, Inc. (0001517022) (Filer)

    5/7/26 7:24:30 AM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Akebia Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Akebia Therapeutics, Inc. (0001517022) (Filer)

    5/7/26 7:05:53 AM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKBA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    CAMBRIDGE, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted one newly-hired employee options to purchase an aggregate of 8,400 shares of Akebia's common stock on May 29, 2026. The options were granted as an inducement material to the employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $1.02 per share, which is equal to the closing price of Akebia's common stock on the grant date. The stock options vest over four years, with 25% of the shar

    6/1/26 4:05:00 PM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Akebia Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference

    CAMBRIDGE, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that Erik Ostrowski, Chief Financial and Business Officer, and Nicholas Grund, Chief Commercial Officer, will present at the 2026 Jefferies Global Healthcare Conference on Thursday, June 4, 2026 at 7:35 AM ET in New York, NY. A live webcast of the presentation can be accessed through the "Investors" section of Akebia's website at https://ir.akebia.com. A replay of the webcast will also be available for 90 days following the presentation. The 2026 Jefferies Global Healthcare Confe

    5/28/26 8:00:00 AM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Akebia Therapeutics Reports First Quarter 2026 Financial Results and Commercial and Pipeline Highlights

    Q1 2026 Vafseo® (vadadustat) net product revenues grew to $15.8 million; Q1 2026 total net product revenues of $52.0 million Number of patients treated with Vafseo increased 60% in Q1 2026 compared to Q4 2025 Akebia hosted virtual R&D Day highlighting robust kidney disease pipeline, outlining clinical trial plans and timing of expected data catalysts Patient enrollment continues to progress in praliciguat Phase 2 clinical trial in focal segmental glomerulosclerosis (FSGS) Akebia to host conference call on May 7, 2026, at 8:00 a.m. EST CAMBRIDGE, Mass., May 07, 2026 (GLOBE NEWSWIRE) --  Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better t

    5/7/26 7:00:00 AM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKBA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright resumed coverage on Akebia Therapeutics with a new price target

    H.C. Wainwright resumed coverage of Akebia Therapeutics with a rating of Buy and set a new price target of $8.00

    6/4/25 7:33:29 AM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leerink Partners initiated coverage on Akebia Therapeutics with a new price target

    Leerink Partners initiated coverage of Akebia Therapeutics with a rating of Outperform and set a new price target of $7.00

    4/28/25 8:36:09 AM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jefferies initiated coverage on Akebia Therapeutics with a new price target

    Jefferies initiated coverage of Akebia Therapeutics with a rating of Buy and set a new price target of $6.00

    4/1/25 9:03:14 AM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKBA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO and President Butler John P. bought $86,588 worth of shares (69,270 units at $1.25), increasing direct ownership by 2% to 3,367,064 units (SEC Form 4)

    4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)

    3/5/26 6:55:46 PM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKBA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Vickers Philip J.

    4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)

    4/3/26 4:06:54 PM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Vickers Philip J.

    3 - Akebia Therapeutics, Inc. (0001517022) (Issuer)

    4/3/26 4:05:32 PM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO and President Butler John P. bought $86,588 worth of shares (69,270 units at $1.25), increasing direct ownership by 2% to 3,367,064 units (SEC Form 4)

    4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)

    3/5/26 6:55:46 PM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKBA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for VAFSEO issued to AKEBIA THERAPEUTICS INC

    Submission status for AKEBIA THERAPEUTICS INC's drug VAFSEO (ORIG-1) with active ingredient VADADUSTAT has changed to 'Approval' on 03/27/2024. Application Category: NDA, Application Number: 215192, Application Classification: Type 1 - New Molecular Entity

    3/28/24 10:46:38 AM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKBA
    Financials

    Live finance-specific insights

    View All

    Akebia Therapeutics Reports First Quarter 2026 Financial Results and Commercial and Pipeline Highlights

    Q1 2026 Vafseo® (vadadustat) net product revenues grew to $15.8 million; Q1 2026 total net product revenues of $52.0 million Number of patients treated with Vafseo increased 60% in Q1 2026 compared to Q4 2025 Akebia hosted virtual R&D Day highlighting robust kidney disease pipeline, outlining clinical trial plans and timing of expected data catalysts Patient enrollment continues to progress in praliciguat Phase 2 clinical trial in focal segmental glomerulosclerosis (FSGS) Akebia to host conference call on May 7, 2026, at 8:00 a.m. EST CAMBRIDGE, Mass., May 07, 2026 (GLOBE NEWSWIRE) --  Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better t

    5/7/26 7:00:00 AM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Akebia Therapeutics to Report First Quarter 2026 Financial Results and Discuss Recent Business Highlights

    Akebia to Host Conference Call on May 7 at 8:00 a.m. EDT CAMBRIDGE, Mass., April 30, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA) today announced plans to release its financial results for the first quarter ended March 31, 2026 on Thursday, May 7, 2026, prior to the open of financial markets. Akebia will host a conference call on Thursday, May 7, 2026, at 8:00 a.m. EDT to discuss its financial results and recent business highlights. To access the call, please register by clicking on this Registration Link, and you will be provided with dial in details. To avoid delays and ensure timely connection, we encourage dialing into the conference call 15 minutes ahead of the

    4/30/26 4:05:00 PM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Akebia Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial and Pipeline Highlights

    Q4 2025 net product revenues of $54.3 million; 2025 full-year net product revenues of $227.3 million, representing a 49% increase over 2024 full-year net product revenues Expect significant Vafseo® (vadadustat) revenue growth in 2026 through expanded access to therapy at dialysis organizations, new patient starts, and improved adherence rates Pipeline advancement continues with enrollment underway for praliciguat Phase 2 clinical trial in focal segmental glomerulosclerosis (FSGS) and AKB-097 Phase 2 rare kidney disease basket trial planned to begin in 2H 2026 Akebia to Host Conference Call at 8:00 a.m. EST on February 26, 2026 CAMBRIDGE, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Ake

    2/26/26 7:00:00 AM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKBA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Akebia Therapeutics Inc. (Amendment)

    SC 13G/A - Akebia Therapeutics, Inc. (0001517022) (Subject)

    2/13/24 4:58:48 PM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Akebia Therapeutics Inc. (Amendment)

    SC 13G/A - Akebia Therapeutics, Inc. (0001517022) (Subject)

    2/9/24 4:00:47 PM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Akebia Therapeutics Inc. (Amendment)

    SC 13G/A - Akebia Therapeutics, Inc. (0001517022) (Subject)

    2/10/23 1:08:17 PM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKBA
    Leadership Updates

    Live Leadership Updates

    View All

    Akebia Therapeutics Appoints Biopharmaceutical Leader Philip Vickers, Ph.D. to its Board of Directors

    CAMBRIDGE, Mass., April 01, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the appointment of biopharmaceutical leader Philip J. Vickers to its Board of Directors, effective April 1, 2026. Dr. Vickers is the President and Chief Executive Officer and a member of the Board of Directors of Solu Therapeutics, a venture-backed biotechnology company focused on creating first-in-class therapeutics utilizing a novel drug discovery platform, and he has held senior leadership positions at several early-stage biotechnology companies as well as global pharmaceutica

    4/1/26 4:05:00 PM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Akebia Therapeutics Announces Appointment of Nicholas Grund as Chief Commercial Officer

    CAMBRIDGE, Mass., Jan. 9, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the appointment of Nicholas Grund as Chief Commercial Officer. Mr. Grund is a seasoned pharmaceutical executive with significant operational, commercial and strategic leadership experience across renal and specialty markets. AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease (PRNewsfoto/Akebia Therapeutics, Inc.)" alt="Akebia Therapeut

    1/9/24 8:30:00 AM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Akebia Therapeutics Appoints Ron Frieson, Healthcare Operations Leader, to Board of Directors

    CAMBRIDGE, Mass., Nov. 1, 2021 /PRNewswire/ -- Akebia Therapeutics®, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the appointment of Ron Frieson to its Board of Directors. Frieson currently serves as the Chief Operating Officer of Children's Healthcare of Atlanta (CHOA), a non-profit corporation whose mission focuses on bettering all aspects of children's healthcare. AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease (PRNewsfoto/Akebia Therapeutics, Inc.)" alt

    11/1/21 8:00:00 AM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care